These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 31701846)
1. Effect of Tumor Suppressor MiR-34a Loaded on ZSM-5 Nanozeolite in Hepatocellular Carcinoma: In Vitro and In Vivo Approach. Salah Z; Abd El Azeem EM; Youssef HF; Gamal-Eldeen AM; Farrag AR; El-Meliegy E; Soliman B; Elhefnawi M Curr Gene Ther; 2019; 19(5):342-354. PubMed ID: 31701846 [TBL] [Abstract][Full Text] [Related]
2. Carboxymethyl Dextran-Stabilized Polyethylenimine-Poly(epsilon-caprolactone) Nanoparticles-Mediated Modulation of MicroRNA-34a Expression via Small-Molecule Modulator for Hepatocellular Carcinoma Therapy. Deng X; Yin Z; Zhou Z; Wang Y; Zhang F; Hu Q; Yang Y; Lu J; Wu Y; Sheng W; Zeng Y ACS Appl Mater Interfaces; 2016 Jul; 8(27):17068-79. PubMed ID: 27300477 [TBL] [Abstract][Full Text] [Related]
3. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma. Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-34a promotes MICB expression in hepatocytes. Zhou MT; Zhao C; Chen X; Zhang HC; Li G; Lou H; Huang WJ; Wei LJ; Li DW; Wu X; Zhang ZC; Liu H; Ou R; Yang WJ; Hu S; Xu Y; Tang KF Carcinogenesis; 2018 Dec; 39(12):1477-1487. PubMed ID: 30256916 [TBL] [Abstract][Full Text] [Related]
5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the diagnostic and therapeutic roles of non-coding RNA and cell proliferation related gene association in hepatocellular carcinoma. Ahmed MY; Salah MM; Kassim SK; Abdelaal A; Elayat WM; Mohamed DA; Fouly AE; Abu-Zahra FAE Gene; 2019 Jul; 706():97-105. PubMed ID: 31034943 [TBL] [Abstract][Full Text] [Related]
7. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop. Xia C; Shui L; Lou G; Ye B; Zhu W; Wang J; Wu S; Xu X; Mao L; Xu W; Chen Z; Liu Y; Zheng M Sci Rep; 2017 Jun; 7(1):4396. PubMed ID: 28667294 [TBL] [Abstract][Full Text] [Related]
8. miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway. Xu X; Chen W; Miao R; Zhou Y; Wang Z; Zhang L; Wan Y; Dong Y; Qu K; Liu C Oncotarget; 2015 Feb; 6(6):3988-4004. PubMed ID: 25686834 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. Komoll RM; Hu Q; Olarewaju O; von Döhlen L; Yuan Q; Xie Y; Tsay HC; Daon J; Qin R; Manns MP; Sharma AD; Goga A; Ott M; Balakrishnan A J Hepatol; 2021 Jan; 74(1):122-134. PubMed ID: 32738449 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. He XX; Chang Y; Meng FY; Wang MY; Xie QH; Tang F; Li PY; Song YH; Lin JS Oncogene; 2012 Jul; 31(28):3357-69. PubMed ID: 22056881 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Long J; Jiang C; Liu B; Fang S; Kuang M Tumour Biol; 2016 May; 37(5):5821-8. PubMed ID: 26581909 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Yang F; Li QJ; Gong ZB; Zhou L; You N; Wang S; Li XL; Li JJ; An JZ; Wang DS; He Y; Dou KF Technol Cancer Res Treat; 2014 Feb; 13(1):77-86. PubMed ID: 23862748 [TBL] [Abstract][Full Text] [Related]
13. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. Xu L; Feng X; Hao X; Wang P; Zhang Y; Zheng X; Li L; Ren S; Zhang M; Xu M J Exp Clin Cancer Res; 2019 Feb; 38(1):98. PubMed ID: 30795787 [TBL] [Abstract][Full Text] [Related]
14. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846 [TBL] [Abstract][Full Text] [Related]
15. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Li F; Wang F; Zhu C; Wei Q; Zhang T; Zhou YL Int J Nanomedicine; 2018; 13():2295-2307. PubMed ID: 29713162 [TBL] [Abstract][Full Text] [Related]
16. miR-23c suppresses tumor growth of human hepatocellular carcinoma by attenuating ERBB2IP. Zhang L; Wang Y; Wang L; Yin G; Li W; Xian Y; Yang W; Liu Q Biomed Pharmacother; 2018 Nov; 107():424-432. PubMed ID: 30103114 [TBL] [Abstract][Full Text] [Related]
17. The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma. Zhang L; Niu H; Ma J; Yuan BY; Chen YH; Zhuang Y; Chen GW; Zeng ZC; Xiang ZL Mol Cancer; 2019 Jul; 18(1):120. PubMed ID: 31349837 [TBL] [Abstract][Full Text] [Related]
18. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Hsu SH; Yu B; Wang X; Lu Y; Schmidt CR; Lee RJ; Lee LJ; Jacob ST; Ghoshal K Nanomedicine; 2013 Nov; 9(8):1169-80. PubMed ID: 23727126 [TBL] [Abstract][Full Text] [Related]
19. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). Zhu Q; Gong L; Wang J; Tu Q; Yao L; Zhang JR; Han XJ; Zhu SJ; Wang SM; Li YH; Zhang W BMC Cancer; 2016 Oct; 16(1):806. PubMed ID: 27756250 [TBL] [Abstract][Full Text] [Related]
20. A redox-sensitive, oligopeptide-guided, self-assembling, and efficiency-enhanced (ROSE) system for functional delivery of microRNA therapeutics for treatment of hepatocellular carcinoma. Hu Q; Wang K; Sun X; Li Y; Fu Q; Liang T; Tang G Biomaterials; 2016 Oct; 104():192-200. PubMed ID: 27459325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]